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Background: Our main objective was to evaluate the ability of cranberry phytochemicals to modify immunity,
specifically γδ-T cell proliferation, after daily consumption of a cranberry beverage, and its effect on health outcomes
related to cold and influenza symptoms.
Methods: The study was a randomized, double-blind, placebo-controlled, parallel intervention. Subjects drank a low
calorie cranberry beverage (450 ml) made with a juice-derived, powdered cranberry fraction (n = 22) or a placebo
beverage (n = 23), daily, for 10 wk. PBMC were cultured for six days with autologous serum and PHA-L stimulation.
Cold and influenza symptoms were self-reported.
Results: The proliferation index of γδ-T cells in culture was almost five times higher after 10 wk of cranberry beverage
consumption (p <0.001). In the cranberry beverage group, the incidence of illness was not reduced, however
significantly fewer symptoms of illness were reported (p = 0.031).
Conclusions: Consumption of the cranberry beverage modified the ex vivo proliferation of γδ-T cells. As these cells
are located in the epithelium and serve as a first line of defense, improving their function may be related to reducing
the number of symptoms associated with a cold and flu.
Trial registration: ClinicalTrials.gov Identifier: NCT01398150.
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Cranberries and cranberry juice are associated with pro-
moting urinary tract health [1,2] However, although the
responsibility of immune cells is to survey their environ-
ment and prevent bacterial and viral infections from
overwhelming the body, much of the literature regarding
cranberry research has focused on adherence of bacteria
[3-6] rather than modification of immune function.* Correspondence: percival@ufl.edu
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stated.Four studies have shown the effects of cranberry on
immune function in diverse ways: in a rabbit model of
infection-induced oxidative renal damage, cranberry re-
duced inflammation [7]; consumption of a cranberry
beverage in a human intervention study resulted in a re-
duction in pathogen in 42% of the subjects without alter-
ing normal vaginal microbiota [6]; lower levels of
urinary IL-6 were found in pregnant women after drink-
ing cranberry juice for at least 3 days [8]; and an en-
hanced generation of anti-lymphoma antibodies was
detected in an immuno-competent mouse model of
lymphoma [9]. Recent studies have shown effectiveness
of cranberry in reducing reoccurrence of urinary tracttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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berry have focused on pyuria and bacteriuria [13,14], but
did not examine the influence on systemic immunity.
These studies suggest that systemic immunity is modified
by the bioactive compounds in cranberries, but have not
directly assessed it.
An immune cell particularly suited to surveillance of
the genitourinary tract is the γδ-T cell, which is stra-
tegically located in the epithelium of both the intestine
and the reproductive tract. We have shown in human
consumption studies with an encapsulated dried fruit
and vegetable juice fraction [15], two compounds de-
rived from tea [16], and Concord grape juice [17], that
various phytochemicals modify ex vivo γδ-T cell prolifera-
tion. Phytochemicals and proanthocyanidins from herbal
preparations also interact with γδ-T cells in vitro [18-20].
Cranberry polyphenols and proanthocyanidins, then,
would seem to be potential candidates for modifying
human immunity.
Our objective was to determine if a polyphenol-
containing fraction of cranberry would have immuno-
modulating activities in humans. Our primary outcome
was proliferation of γδ-T cells ex vivo; however, the pro-
liferation of other immune cells was also examined. Our
secondary outcome was the evaluation of illness symp-
toms during the 10-week study.
Materials and methods
Subjects
A total of 54 healthy subjects (17 men and 37 women),
ranging in age from 21 to 50 years, with a body mass
index between 18 and 30 kg/m2, were recruited by
posted advertisements to participate in a 10-wk, double-
blind, randomized, placebo-controlled, parallel trial. The
University of Florida Institutional Review Board ap-
proved the study protocol, and informed written consent
was obtained from each subject. Subjects were required
to be generally healthy, and exclusion criteria were: tak-
ing immunosuppressive drugs, recent or chronic anti-
biotics, antioxidant supplements or probiotics, or any
flavonoid-containing supplements; lactating or being
pregnant or on hormone therapy; being a chronic user
of non-steroidal anti-inflammatory drugs; having an on-
going infection or hypertension that required medica-
tion; consuming more than 14 alcoholic beverages per
week, eating more than 7 fruits and vegetables per day
or following a vegetarian or strict vegan diet. Partici-
pants were not allowed to begin the study if they were ill
at the time of the first blood draw. Participants were in
contact with the enrolling research assistant by e-mail
and telephone, weekly or more often, throughout the
study.
The predefined primary outcome was proliferation of
γδ-T cells in ex vivo culture. Power analysis, (α = 0.05and power = 0.80), based on data where a difference
would be significant if the proliferation of γδ-T cells was
double that of the placebo group with an expected
standard deviation of 1.74, indicated that 13 subjects
would be needed per group to detect a statistical differ-
ence. A predefined level of compliance was consumption
of 80% of the allotted juice.
Study design
The study was conducted between March and May of
2009, to coincide with normal cold and influenza season
in the Southeast (CDC, http://www.cdc.gov/flu/; accessed
October 2011). The CDC weekly report of influenza activ-
ity in the state of Florida that year was as follows: March,
widespread to regional activity; April, local to sporadic ac-
tivity; May, regional to local activity.
Subjects arrived to the Food Science and Human Nutri-
tion building, for an initial baseline fasting blood draw
(Day 0) and were randomly assigned, by drawing cards
from an opaque envelope that were numbered either 246
or 638, to receive the experimental treatment [cranberry
beverage (CB)] or a placebo beverage (PB), both provided
by Ocean Spray Cranberries, Inc. (Lakeville, MA). Both
subjects and investigators were blinded regarding the
treatment groups. The CB contained cranberry com-
ponents from juice, filtered water, sugar, natural flavors,
citric acid, and sucralose. The PB was a color-(Red 40 and
Blue 1), calorie-, and sweetener-matched beverage without
cranberry components. The experimental beverage is not
commercially available, but was formulated to contain a
level of polyphenols similar to that found in commercially
available cranberry juice cocktails. The fraction of cran-
berry components used, derived from the juice of cran-
berries, was prepared and analyzed by the manufacturer
(Table 1). High-performance liquid chromatography ana-
lysis of the fraction used to prepare the beverage was con-
ducted (manuscript submitted).
Subjects were given bottles containing 450 ml (15 oz)
of beverage and instructed to drink one bottle through-
out the day, each day, for 70 days (10 wk). Participants
were supplied with more bottles than were needed to
complete the study, in case scheduling conflicts delayed
the second blood draw. To prevent bottles from being
discarded, subjects were instructed to bring back any
remaining bottles at the end of the study.
Participants were also given a daily illness log to rec-
ord any cold and influenza symptoms (listed below) they
experienced during the 10-wk experimental period. Each
day they had to answer this question: Did you have any
illness symptoms today? If they answered yes, then they
were asked to check the box with each of the symptoms
they had that day.
The primary outcome of this study was defined, prospect-
ively, as physiological changes to γδ-T cell proliferation in
Table 1 Chemical characterizationa of the cranberry
treatment and placebo beverages
Cranberry beverage Placebo beverage
Proanthocyanidins, % dwbb 65-77% 0-1%
Sugars, % dwb 0.77-1.12% 0%
Anthocyanins, % dwb 6.8-11.3% Not detected
Organic acids, % dwb 0.5-0.9% 0.1-0.2
Phenolic acids, % dwb 7.1-7.5% Not tested
Flavonols, % dwb 6.8-10.0% Not tested
Total Solids,% dwb 87.0-107.8% 0.1-1.2%
Sucralose (μg/mL) 152 149
Vitamin C Not detected Not detected
ORACc (μM AA/g) 62.1 Not detected
Colorant (Red 40/Blue 1) None 1%
Brix by refractometry (o) 0.25 0.23
aCharacterization of the beverages was by standard methodology and
performed by the manufacturer of the beverages. Values were assessed in the
lab of SSP by standard methodology and were computed against an ascorbic
acid (AA) standard curve. bdwb, dry weight basis cORAC, oxygen radical
absorbance capacity.
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ondary outcomes because of the small number of subjects,
and because they were self-reported. These outcomes
were defined as incidence (number of people reporting an
illness per group and the number of illnesses per group),
duration (total number of days with at least two symptoms
and average number of days per group), and total number
of symptoms per group. Symptoms listed in the daily diary
were: runny or congested nose, cough, sneezing, fever
and/or chills, sore throat, headache, wheezing, and intes-
tinal distress (nausea, vomiting, diarrhea, and/or abdom-
inal cramps). Allergy symptoms were not included in the
analysis of symptoms. Subjects were instructed as to the
different manifestations of colds, influenza and allergies:
Colds–symptoms occur one at a time, generally last for
5-7 days, yellow/greenish nasal discharge, may or may not
be accompanied by a fever, with slight body aches and
pains; Influenza–symptoms occur rapidly, last up to
14 days, no nasal discharge, often a high fever and some-
times chills, with severe body aches and pains, including
headache; Allergy–symptoms occur rapidly and all at
once, last as long as the allergy-causing agent is present,
clear and watery nasal discharge, not associated with a
fever, and no body aches or pains. The record of the medi-
cations taken during an illness also helped to distinguish
allergy from colds and influenza. Subjects were asked to
report if they missed class or work, whether they sought
medical treatment, if they were prescribed any medica-
tions as a result of seeking treatment, which over-the-
counter medications they took, and whether they had a
significant decrease in normal activities due to illness
symptoms.At 10 wk, study participants returned for a final blood
draw and to complete an exit questionnaire. The exit
questionnaire included questions to determine if sub-
jects experienced any side effects from the beverage,
their estimate of compliance and if they generally ad-
hered to the inclusion/exclusion criteria. To determine
efficacy of blinding, subjects reported whether they
thought they had received the CB or the PB and were
asked why they believed that. Study compliance was
assessed by comparing the number of bottles of beverage
returned at the end of the study (primary assessment of
compliance) with the number they should have returned.
Blood collection and peripheral blood mononuclear cell
(PBMC) isolation
Blood was obtained from fasting subjects on Day 0
(baseline) and at 10 wk. Fasting required eating no food
after midnight of the previous day. Blood was collected
into one 10 ml sodium heparin tube for PBMC isolation,
and one 10 ml SST™ tube (Vacutainer, Becton Dickinson,
Franklin Lakes, NJ) to obtain serum. All tubes were
processed within 2 h of blood collection. Serum was re-
moved from SST™ tubes after centrifugation (2,000 × g,
10 min, 4°C) and used as autologous serum in culture
media. Aliquots of serum were frozen at−80°C for anti-
oxidant analysis. Whole blood was diluted 1:1 with 0.9%
NaCl and layered on a gradient (Lympholyte® H Cell Sep-
aration Media, Cedarlane Laboratories Ltd., Burlington,
NC) to separate PBMC by centrifugation (800 × g, 20 min,
20°C). The mononuclear cell layer was removed and
washed twice with RPMI 1640 (Cellgro, Mediatech, Inc.,
Manassass, VA) complete medium (100,000 U/L penicil-
lin; 100 mg/L streptomycin; 0.25 mg/L fungizone; 50 mg/
L gentamicin; 2 mmol/L L-glutamine; 25 mmol/L HEPES
buffer). Cell pellets were resuspended in RPMI 1640
complete medium and counted on a hemocytometer.
Culture of PBMC for proliferation and cytokine production
On Day 0, 1.0 × 106 PBMC in RPMI 1640 complete
medium containing 50 μM 2-ME and 10% autologous
serum were seeded into two wells of duplicate 24-well tis-
sue culture plates (Costar, Corning Incorporated, Corning,
NY). Phytohemagglutinin (PHA-L from Phaseolus vul-
garis) at a final concentration of 10 μg/ml, was added to
one set of wells on each plate, while the other set was
brought to volume with RPMI 1640 complete medium.
The plates were incubated at 37°C in a humidified 5%
CO2 atmosphere. After 24 h, supernatant fluids from one
plate were harvested and frozen at−80°C for future cyto-
kine analysis. On Day 3, human recombinant IL-2 (BD
Biosciences, San Jose, CA), at a concentration of 1 ng/ml,
was added to all wells of the second plate, which was incu-
bated until Day 6 when cells were harvested and proc-
essed for flow cytometry.
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PBMC were analyzed by flow cytometry on Days 0 and 6
of culture, using cell surface markers for identification.
Specific cell population numbers were expressed as a
percentage of total cells [B cells, monocytes and natural
killer (NK) cells] or as a percentage of the CD3+ popula-
tion (αβ-T cells and γδ-T cells). To determine prolifera-
tion changes of the various cell types at both blood
draws, the fold change of individual subjects was calcu-
lated as the ratio of numbers of cultured cells to uncul-
tured cells (Day 6/Day 0). If no proliferation occurred
during that time, the ratio would equal 1.0. Then, the
fold change before beverage consumption (baseline) was
subtracted from the fold change after consumption
(10 wk). Antibodies were obtained from eBioscience, Inc.
(San Diego, CA) and used to detect specific cell types, as
follows: γδ-T cells (PE-CD3 and FITC-γδ-TCR); αβ-T
cells (PE-CD3 and FITC- αβ-TCR); NK cells (PE-CD314
and FITC-CD56); B cells (PE-CD19) and Monocytes
(FITC-CD14). After staining, cells were washed and fixed
with 1% paraformaldehyde. Data was acquired on a BD
Biosciences FACSort flow cytometer with CellQuest Pro
software (BD Biosciences, San Jose, CA) within 48 h.
FlowJo Analysis Software, version 7.5 (Tree Star, Inc.,
Ashland, OR) was used for data analysis.
Cytokine level determination in cell culture supernatant
fluids
Levels of cytokines (IFN-γ, IL-1α, IL-1β, IL-13, MIP-1β,
and TNF-α) secreted by PBMC in culture for 24 h, were
quantified using a Human Cytokine Multiplex Immuno-
assay kit, according to the manufacturer’s directions
(Millipore Corp., Billerica, MA). Standards and controls
were provided with the kit. The beads were analyzed on
a Luminex® 200 instrument (Luminex Corporation,
Austin, Texas) with xPONENT 3.1 software. In addition,
levels of IL-17 were determined by ELISA according to
manufacturer’s directions (eBioscience, San Diego, CA)
with kit standards and controls. The fluids were thawed
on ice and used undiluted in the assay. Final absorbance
was measured at 450 nm on a SPECTRAmax 340PC
plate reader and data analyzed using SOFTmax® Pro 5.2
(Molecular Devices, Sunnyvale, CA). All values are ex-
pressed as pg/ml.
Serum oxygen radical absorbance capacity (ORAC)
The ORAC assay consisted of monitoring the inhibition of
decay of fluorescein in the presence of the peroxyl radical
generator 2,2′azobis 2-amidinopropane dihydrochloride
(AAPH). The rate of fluorescence decay was monitored
over time by calculating the area under the fluorescent
decay curve and quantified using a standard curve of
Trolox (0.312-2.5 μM, Fluka Chemical/Sigma). Antioxi-
dant activity in protein-free sera was determined using theORAC assay, as previously described [21,22] for a 96-well
microplate reader, with some modifications. Briefly, at col-
lection sera were diluted 1:5 in 6% meta-phosphoric acid
and frozen at -80°C. After thawing, they were centrifuged
to precipitate protein (12,000 × g, 5 min, 4°C) and diluted
1:10 in phosphate buffer. Then, 50 μl of each sample were
pipetted into duplicate wells. Serum samples for quality
control were prepared in our laboratory and used in each
assay plate to determine variability. Plate to plate variabil-
ity was 7.1%. Fluorescein solution (20 nM) was added to
all wells. The plate was mixed for 3 minutes, and then
equilibrated for 7 minutes to 37°C in a SPECTRAmax
GeminiXPS fluorescent plate reader (Molecular Devices,
LLC, Sunnyvale, CA). Freshly prepared AAPH free-radical
solution (140 mM in phosphate buffer) was added (50 μl),
and the FITC fluorescence decay was monitored at 32-sec
intervals for 40 min (excitation, 485 nm; emission, 538 nm;
cutoff, 530 nm). ORAC values were calculated as the area
under the curve using SOFTmax® Pro 5.2 Software
(Molecular Devices, LLC, Sunnyvale, CA), and the data
expressed in μmol Trolox equivalents.
Statistical analysis
For the cytokine and immune cell measures, a non-
parametric Wilcoxon/Kruskal-Wallis Rank sum test was
performed on the differences in levels before and after
supplementation. Illness and symptom data was analyzed
by logistical regression with a generalized linear model
and an exponential distribution. An over-dispersion par-
ameter was used, due to larger-than-expected variance
(JMP, version 8, Cary, NC). A nominal alpha level of 0.05
was used to declare statistical significance. A sub-group
analysis of all primary indices was performed to determine
and to address blinding issues, comparing those who
guessed correctly (n = 5) with those who did not.
Results
Of 68 people assessed for eligibility, 54 individuals en-
rolled in the study (Figure 1). During the study, 9 people
withdrew: six because they were unable to return for the
final blood draw, two because of the taste of the beverage,
and one with no explanation. Of the 54 subjects enrolled,
45 (83%) completed the study. Overall compliance, deter-
mined by returned bottle count, was 96.1% ± 3.7% bottles
of beverage (Table 2). All participants consumed at least
80% of their allocated beverage; therefore, no one was ex-
cluded from data analysis based on noncompliance.
Regarding blinding, all subjects (100%) in the placebo
group thought they were drinking the PB, while only five
of the 22 people in the experimental treatment group
(23%) guessed they were drinking the CB (Table 2). As
there was a significant difference between the proportion
of people guessing correctly versus the proportion of





Not meeting inclusion/exclusion criteria     
(n=7)
Would not consume red dye or 





Excluded from analysis 
(n=0)













1 unable to return for final blood draw
2 did not like sucralose taste of juice








Randomized into  
treatment groups 
#638 or #246
Unable to be present for blood draws  
(n=54)
Figure 1 Flow diagram: Study participant eligibility assessment, enrollment, group allocation and analysis. People recruited for the study
were assessed and those deemed eligible were enrolled. Subjects were randomized into one of two beverage groups. Bottles of the two
beverages, cranberry and placebo, were received from Ocean Spray Cranberries, Inc. and labeled either #638 or #246. Subjects and investigators
were blinded regarding the treatment groups. Statistical analysis was performed on data from all subjects completing the study. Investigators
were unblinded (cranberry beverage: #638; placebo beverage: #246) following completion of the data analysis.
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were on the placebo, bias toward treatment was not an-
ticipated to influence outcome. A subgroup analysis in-
dicated that there were no significant differences in any
of the parameters, but one, when comparing who guessed
correctly with who guessed incorrectly. Those in the
group that guessed correctly had slightly higher MIP1α
levels at baseline compared to 10 week, or compared to ei-
ther time point of those who did not guess correctly. In-
teractions between guessing correctly and time were not
significant. Since this was observed in the baseline value,
before anyone started the study, the biological significance
of this statistical difference is unknown.
The total incidence of colds and influenza were not sta-
tistically different between the two groups (Table 2). How-
ever, the proportion of the total number of symptoms was
statistically lower in the CB drinking group (p = 0.031).
Since only 11.1% of the subjects thought they were con-
suming the active treatment, a bias by what they thought
they were drinking was not suspected. The report of intes-
tinal distress as a symptom was statistically greater(p = 0.021) in the PB group, as compared to the CB
group. No other symptom showed any statistical differ-
ence. However, because subjects in the placebo group re-
ported a few more symptoms in each category, the total
number of symptoms was proportionally greater in that
group compared to the CB group, and total symptoms
were statistically different between the groups.
The percentage of specifically labeled PE+-FITC+ cells
in the lymphocyte population (FSC/SSC) was deter-
mined at the blood draws before and after consumption,
in both freshly isolated PBMC and in PBMC that were
cultured for six days. Proliferation of γδ-T cells was sig-
nificantly improved after CB consumption (Table 3)
compared to the placebo. NK cell proliferation did not
achieve significance when treatments were compared.
There was no effect of CB on αβ-T cells, B cells or
monocytes. The antioxidant activity of the serum was
determined in de-proteinated samples, but the groups
were not statistically different (data not shown).
Cytokine levels in the supernatant fluids of 24 h
PBMC cultured with PHA-L were determined, resulting
Table 2 Demographics and cold and influenza symptoms
Characteristic Placebo beverage Cranberry beverage P
Demographic
n 23 22
Age (y) ± SDa 24.0 ± 3.3 24.9 ± 5.8
Male 5 9
Female 18 13
BMIb, initial 21.5 ± 2.7 23.2 ± 4.0 0.103
Change in BMI (kg/m2) ± SD −0.095 ± 0.52 −0.063 ± 0.37 0.810c
No. blinded/guessed correctly (%) 23/23 (100) 5/22 (23) <0.001
Complianced (%) ± SD 96.3 ± 4.6 95.9 ± 3.7 NSDe
Cold and Influenza Symptoms
nf 20 15 0.624
Total incidenceg 31 21 0.282h
Total cold and influenza symptoms 354 297 0.031h
Incidence of intestinal distress 35 15 0.021h
Total days missed work/school 29 20 0.329h
Total times reported a decrease in activity 28 16 0.154h
aSD, standard deviation bBMI, body mass index cp value derived from t-test dBased on bottle count eNSD, not significantly different fNumber of people who
reported symptoms gNumber of colds and cases of influenza reported. Some individuals had more than one illness during the 10 wk period hP value derived from
z-test of proportions.
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fore, the change between cytokine secretion at 10 wk
and secretion at baseline was compared between the pla-
cebo and treatment groups (Table 4). The ability of
PBMC to secrete interferon-γ (IFN-γ) was significantly
increased after CB consumption (p = 0.041). Other mea-
sured cytokines were not statistically different.Discussion
The primary predefined outcome measure was a change
in the ability of γδ-T cells derived from peripheral blood
immune cells to proliferate in ex vivo culture. The γδ-TTable 3 Immune cell proliferationa fold changeb after
cranberry beverage consumption
Cell type Placebo beverage Cranberry beverage P
γδ-T cellc 1.20 ± 0.26f 3.86 ± 0.50 <0.001
NKd celle 0.15 ± 0.12 0.33 ± 0.19 0.068
αβ-T cellc −0.16 ± 0.09 −0.16 ± 0.08 0.602
Monocytee −0.11 ± 0.29 −0.30 ± 0.45 0.883
B cellse 0.81 ± 0.16 1.32 ± 0.40 0.235
aAfter isolation (Day 0), cells were placed into culture in RPMI-1640 with
autologous serum and PHA-L, IL-2 and IL-15 for 6 days bA ratio of cultured cell
numbers (Day 6/Day 0) was used to calculate proliferation fold changes.
Baseline fold change values were subtracted from values obtained at 10 wk
cPercentage of the CD3+ population determined by 2-color staining dNK,
natural killer ePercentage of total cells fWilcoxon/Kruskal-Wallis rank sums test
was used to determine significant differences. Values were calculated for each
subject and the mean ± SEM determined.cells showed an improved ability to proliferate in culture
with PHA-L, after the CB was consumed. The cranberry
fraction powder was prepared from the juice of cran-
berries and one serving of the low calorie CB (450 ml)
contained polyphenol levels comparable to a serving of
cranberry juice cocktail (250 ml). The proanthocyanidin
fraction contained both A-and B-type linkages. Cran-
berries are known to have high antioxidant activity, yet
serum antioxidant activity was not different between the
groups or from baseline to 10 wk (data not shown).
Pharmacokinetic studies that measure immediate accu-
mulation of polyphenols in blood show that the turnover
is rapid; about 2-4 hours [23-25]. Thus, a lack of change
in serum antioxidant activity is not surprising whenTable 4 Cytokines secreted by PBMCa during 24 h cultureb
Cytokine Placebo beverage Cranberry beverage Pc
IL-1β −519.7 ± 115.5d −187.8 ± 107.1 0.088
IFN-γ −24.8 ± 33.4 148.1 ± 80.2 0.041
TNF-α 189.7 ± 155.9 367.2 ± 140.2 0.452
IL-17 16.8 ± 11.3 26.2 ± 16.7 0.973
IL-1α −36.5 ± 20.0 −27.9 ± 29.7 0.496
MIP-1β 968.3 ± 533.1 1120.0 ± 470.3 0.395
IL-13 −3.1 ± 7.1 −11.5 ± 10.6 0.156
aPBMC, peripheral blood mononuclear cells bOn Day 0, PBMC were cultured in
RPMI-1640 with autologous serum and PHA-L, IL-2 and IL-15 cP values are two-
tailed based on the Wilcoxon/Kruskai-Wallis Rank sum test dValues reported
are the mean changes ± SEM of the 10-wk data minus the baseline data.
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this study.
We propose that γδ-T cell proliferation ex vivo is a
surrogate marker for immune function. We have shown
in previous studies that their proliferation can be modi-
fied by diet [15-17]. The issue of bioavailability must be
addressed since many studies show that polyphenols do
not accumulate in the blood, but are rapidly metabo-
lized. Intestinal immune cells are able to interact with
the contents of the lumen because of their location in
the Peyer’s patches and the intra-epithelium. Migration
of intestinal immune cells is well documented [26,27]
and migration patterns have been shown to be influ-
enced by diet [28,29]. Although data specifically regard-
ing γδ-T cells is lacking, we hypothesize that we measure
changes in blood immune cells because they migrate
after they have interacted with luminal bioactive com-
pounds in the intestine.
In addition, larger molecules, at times, are able to
translocate across the intestine and find their way to
cells in the lamina propria and the mesenteric lymph
nodes. Bacterial toxins are found intact in the blood
or lymph [30,31]. Proteins are absorbed intact [32,33]
and procyanidin dimers are transferred to the serosal
side of enterocytes in the isolated small intestine [34]
or in a Caco-2 cell model [35]. Jutila’s group has
shown that the proanthocyanidin content of herbs in-
teracts with receptors on the γδ-T cell and primes
that cell [36]. After priming, the cell is able to re-
spond faster, and to a greater extent, than if it were
not primed. Direct interaction of dietary components
in the lumen, or translocation of dietary components
into the lamina propria, could result in priming of
immune cells. Finally, changes detected in systemic
blood cells may also occur because of the fermenta-
tion of unabsorbed polyphenols in the large intestine,
resulting in bioactive compounds that are subse-
quently absorbed. The study was not designed to dis-
tinguish among these different mechanisms.
Changes in immune function may be responsible for a
reduced number of cold and influenza symptoms. Al-
though the incidence of colds and influenza were similar
between the two groups, the total number of symptoms
was lower after consuming the CB. Combining ‘missed
work’ and ‘lower ability to perform a normal daily rou-
tine’ resulted in a p value of 0.056. This study was not
powered on cold and influenza symptoms; it does not
achieve statistical significance, so the idea that cranberry
consumption has an effect on a health outcome is only a
suggestion. Furthermore, the data on cold and influenza
symptoms were self-reported and physicians did not
confirm the presence of cold or influenza pathogens.
However, Macintyre and Pritchard demonstrated that
self-reported symptoms, as well as symptom severity,was highly correlated with assessments made by physi-
cians [37], therefore we feel confident that the symptoms
reported by the subjects accurately reflect the symptoms
they had.
We examined cytokines based on previous in vitro
data (manuscript submitted) in which PBMC from hu-
man donors were incubated with various cranberry frac-
tions. For evaluation in this study, we chose those
cytokines that were secreted in response to the addition
of the cranberry fractions. The results from participants
in this study showed the response of the cells to ex vivo
stimulation was extremely variable. Drawing firm con-
clusions about the role cranberry plays in cytokine pro-
duction is premature, yet the data suggest that cranberry
contributes to an anti-inflammatory effect. Cranberry
proanthocyanidins have been suggested as being anti-
inflammatory in in vitro studies [38,39] and in rabbits
[7]. One human intervention study showed that the level
of urinary IL-6 was reduced in pregnant women who
consumed cranberry juice compared to a placebo [8], yet
other cytokines measured in that study did not achieve
statistical significance, perhaps due to the small n of
each group.
Conclusions
In summary, daily consumption of a cranberry beverage
containing cranberry polyphenols and proanthocyanidins
at levels similar to commercially available juice for 10
wk, was effective in increasing the proliferation response
of γδ-T cells and perhaps NK cells. Overall, the im-
proved proliferation response was coupled with lower
production of an inflammatory cytokine. Improvement
of functional immunity, particularly of a cell located in
the epithelium and responsible for barrier protection,
might be another mechanism by which cranberry is able
to maintain urinary tract health. These physiological
changes could be, in part, responsible for our beneficial
health outcome, a reduction of the number of illness
symptoms.
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